Lower Limbs Erosions Induced by Sunitinib

Kluger, Nicolas; Chapelle, Angélique; Jacot, William; Guillot, B.

doi:10.2340/00015555-1016

Cited by 4 publications

(1 citation statement)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib is a multikinase inhibitor that targets the platelet-derived growth factor (PDGF)-α, PDGF-β, vascular endothelial growth factor receptor (VEGFR)-1–3, c-Kit, FMS-like tyrosine kinase-3 (FLT3), colony stimulating factor 1 (CSF-1), and rearranged during transfection (RET) receptor that is typically used in the treatment of renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumors. 3 – 5 PG-like ulcerations due to sunitinib have been suggested to be due to the antiangiogenic effects of sunitinib by c-Kit and VEGFR inhibition that induce necrosis and subsequent invasion of neutrophilic granulocytes causing this neutrophilic dermatosis ( Figure 1 ). The mainstay of therapy for severe adverse drug reactions is discontinuation of the suspected medication.…”

Section: Introductionmentioning

confidence: 99%

Pyoderma gangrenosum–like ulceration of the lower extremity secondary to sunitinib therapy: a case report

Pineiro¹,

Willis²,

Chen³

et al. 2018

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor used for the treatment of multiple different types of malignancies. Serious grade 3–4 adverse events occur in <10% of the patient population and usually improve with dose reduction. One of the more rarely reported side effects of sunitinib therapy is the development of pyoderma gangrenosum–like ulcerations in the lower extremities. These pyoderma gangrenosum–like ulcerations are difficult to treat and distinguish from similar-appearing dermatological diagnoses. We present a patient with refractory lung carcinoma and a past medical history of squamous cell carcinoma of the lower extremity, who developed a non-healing ulceration at the previous site of her skin cancer while undergoing therapy with sunitinib. At the time of the initial evaluation, the ulceration mimicked recurrent squamous cell carcinoma, posing a diagnostic challenge. Histopathological findings showed epidermal hyperplasia, ulceration, and dense acute inflammation. Despite meticulous wound care and treatment of infection, the ulcer only improved with cessation of sunitinib.

show abstract

Section: Introductionmentioning

confidence: 99%

Pyoderma gangrenosum–like ulceration of the lower extremity secondary to sunitinib therapy: a case report

Pineiro¹,

Willis²,

Chen³

et al. 2018

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

Considerations for Thermal Injury: The Elderly as a Sensitive Population

Bjerke¹

2015

Textbook of Aging Skin

View full text Add to dashboard Cite

Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab

Ara

Pastushenko

2014

Actas Dermo-Sifiliográficas

View full text Add to dashboard Cite

As new antiangiogenic therapies have been introduced and added to the therapeutic arsenal against various types of cancer, previously unknown adverse effects have been detected. These effects negatively impact patients' quality of life and can even make it necessary to suspend treatment. Adverse skin reactions occur in 90% of patients treated with angiogenesis inhibitors. In some cases, a correlation has been observed between the severity of reactions and treatment efficacy and tumor response. It is therefore extremely important that dermatologists be able to recognize and manage these reactions. Moreover, in order to avoid the unjustified withdrawal of potentially life-extending treatments, dermatologists must be able to differentiate between non-life-threatening reactions and life-threatening reactions that necessitate the suspension of treatment. In this review article, we analyze the main cutaneous adverse effects of the most common antiangiogenic agents.

show abstract

Lower Limbs Erosions Induced by Sunitinib

Cited by 4 publications

References 6 publications

Pyoderma gangrenosum–like ulceration of the lower extremity secondary to sunitinib therapy: a case report

Pyoderma gangrenosum–like ulceration of the lower extremity secondary to sunitinib therapy: a case report

Considerations for Thermal Injury: The Elderly as a Sensitive Population

Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab

Contact Info

Product

Resources

About